Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The objective of the first part of the study is to determine a safe dose of TRU-016 that can
be used in combination with bendamustine in patients with relapsed CLL. The objectives of the
second part of the study are to compare the safety and efficacy of TRU-016 in combination
with bendamustine to bendamustine alone in patients with relapsed CLL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aptevo Therapeutics Emergent Product Development Seattle LLC